In the BioHarmony Drug Report Database
Lurbinectedin
Zepzelca, Lurbinectedin (lurbinectedin) is a small molecule pharmaceutical. Lurbinectedin was first approved as Zepzelca on 2020-06-15. It is used to treat small cell lung carcinoma in the USA. Zepzelca’s patent is valid until 2024-12-13 (FDA).
Trade Name
|
Lurbinectedin |
|---|---|
Common Name
|
lurbinectedin |
ChEMBL ID
|
CHEMBL4297516 |
Indication
|
small cell lung carcinoma |
Drug Class
|
Ecteinascodin derivatives |
Image (chem structure or protein)